For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
Visualization of HIV reservoirs
With Dr. Réjean Thomas and Dr. Daniel E. Kaufmann
After clicking PLAY, click on the lower bar’s subtitles icon for english subtitles.
- Viral reservoirs: the main source of the infection restarting when ARV treatments are interrupted
- Research: characterizing HIV reservoirs with the aim of developing treatments to eliminate them
- Various treatment strategies
to counter the reservoirs:
and deep latency
This activity is supported
by an educational grant from:
After explaining what HIV reservoirs are, Dr. Daniel Kaufmann, Associate Professor in the Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, Université de Montréal, gives a brief overview of the various treatment strategies currently being tested in order to intervene specifically on these reservoirs. These reservoirs contain HIV in a latent state, and are the main source of the infection restarting when antiretroviral treatments are interrupted.
Until now, HIV has been eliminated only in one patient: Timothy Brown, known as “the Berlin patient.” Dr. Kaufmann explains the very special circumstances that led to the full recovery of this formerly HIV-positive patient, who also suffered from an acute form of leukemia.
Réjean Thomas, MD, Dhc
CEO – Founder
Clinique médicale l’Actuel: Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Daniel E. Kaufmann, MD
Department of Microbiology, Infectious Diseases and Immunology
Faculty of Medicine
Université de Montréal
IN COLLABORATION WITH
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Réjean Thomas, MD, Dhc has a financial interest/relationship or affiliation with:
Advisory Boards: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare
Daniel E. Kaufmann, MD, PhD has a financial interest/relationship or affiliation with:
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.